Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi (SNY) to Release Earnings on Thursday
01:20am, Thursday, 16'th Apr 2026
Sanofi (NASDAQ: SNY - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect Sanofi to post earnings of $0.9330 per share and reve
Stock Market Today (LIVE): PPI Beats Fear, But Oil Risks Loom; Novo's OpenAI Deal Lifts Shares
09:33am, Tuesday, 14'th Apr 2026
Top insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
10:46am, Monday, 13'th Apr 2026
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
01:01pm, Tuesday, 07'th Apr 2026
Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.
Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
01:00am, Tuesday, 07'th Apr 2026
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in mod
Aberdeen Group plc Buys 86,314 Shares of Sanofi $SNY
03:08am, Monday, 06'th Apr 2026
Aberdeen Group plc lifted its stake in shares of Sanofi (NASDAQ: SNY) by 22.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 467,2
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
01:16pm, Tuesday, 31'st Mar 2026
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Euro Pacific Asset Management LLC Takes Position in Sanofi $SNY
05:04am, Tuesday, 31'st Mar 2026
Euro Pacific Asset Management LLC acquired a new stake in shares of Sanofi (NASDAQ: SNY) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease
01:00am, Tuesday, 31'st Mar 2026
Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medici
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
EU regulator backs Sanofi's injectable version of blood cancer drug
09:36am, Friday, 27'th Mar 2026
French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version of its blood cancer drug administered through an on-body injector.
Press release: Availability of the Q1 2026 aide-mémoire
02:30am, Tuesday, 24'th Mar 2026
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
07:57am, Monday, 23'rd Mar 2026
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune disease
